CONCENTRATIONS OF SERUM AMYLOID PRECURSOR PROTEIN IN BLOOD AT PATIENTS WITH JUVENILE RHEUMATOID ARTHRITIS AND PROTEINURIA

AIM OF RESEARCH. To estimate concentrations of serum amyloid precursor protein (serum amyloid A protein – SAA) in blood of children with juvenile rheumatoid arthritis (JRA), to compare SAA concentration with pathology of urine analyses. PATIENTS AND METHODS. 60 children with JRA were examined. Сoncentration SAA in blood of patients was measured by an enzyme linked immunoelectrodiffusion essay. Dynamics of clinical urine analyses, daily proteinuria, total protein value, serum albumin value, glomerular filtration rate (GFR) were estimated by endogenous creatinine clearance. RESULTS. 31 of 60 patients (51,7%) had normal urine analyses. 29 patients (48,3%) had proteinuria, 28 from them had daily proteinuria value less than 1g/m2/24h. One patient with rheumatoid renal amyloidosis because of long-standing systemic JRA had proteinuria up to 33g/m2/24h, GFR - 40 ml/min, maximal SAA concentration 828 mg/l. 59 of 60 patients with JRA had normal GFR according to endogenous creatinine clearance. Increased blood SAA concentration (292,3±30,9 mg/l) was revealed in 56 of 60 children (93,3%). In 31 patients with JRA without proteinuria in 28 (90,3%) was observed increased SAA concentration (205,7±44,3 mg/l). In 28 of 29 patients with proteinuria (96,6%) was determined increased blood SAA concentration (378,8±36,7 mg/l). SAA concentration in 28 patients with proteinuria (378,8±36,7 mg/l) was authentically higher than SAA (205,7±44,3 mg/l) in blood of 28 patients without proteinuria. CONCLUSION. In 93,3% patients with JRA increased blood SAA concentration was determined. The results revealed that blood SAA concentration in patients with JRA and proteinuria was higher than in patients without proteinuria.

1. Алексеева ЕИ, Шахбазян ИВ. Ювенильный ревматоидный артрит. В: Самсыгина ГА, Щербакова МЮ, ред. Кардиология и ревматология детского возраста. ИД Медпрактика-М, М., 2004; 744

2. Баранов АА, Баженова ЛК, ред. Детская ревматология. Медицина, М., 2002; 336

3. Алексеева ЕИ, Литвицкий ПФ. Ювенильный ревматоидный артрит: этиология, патогенез, клиника, алгоритмы диагностики и лечения. ВЕДИ, М., 2007; 308

4. Насонов ЕЛ, ред. Ревматология: Клинические рекомендации. ГЭОТАР-Медиа, М., 2011; 752

5. Новик ГА, Абакумова ЛН, Летенкова НМ и др. Ювенильные артриты – опыт диагностики и лечения. Лечащий врач 2008; (4): 23-27

6. Воронцов ИМ, Дубко МФ, Летенкова НМ и др. Ювенильные артриты. Опыт диагностики, клинического группирования и терапии. Вестн Педиатрической академии 2004: 13-19

7. Youn-Soo Hahn, Joong-Gon Kim. Pathogenesis and clinical manifestations of juvenile rheumatoid arthritis. Korean J Pediatr 2010; 53(11): 921-930

8. Папаян АВ, Савенкова НД, ред. Клиническая нефрология детского возраста. Левша. Санкт-Петербург, СПб., 2008; 600

9. Саркисова ИА. Ревматоидный артрит как ведущая причина развития вторичного АА-амилоидоза (Обзор литературы). Нефрология и диализ 2006; 8(1): 15-26

10. Kwang NK. Treatment of juvenile rheumatoid arthritis. Korean J Pediatr 2010; 53(11): 936-941

11. Sokka T, Envalds M, Pincus T. Treatment of rheumatoid arthritis: a global perspective on the use of antirheumatic drugs. Mod Rheumatol 2008; 18: 228–239

12. Савенкова НД, Папаян АВ. Нефротический синдром в практике педиатра. Эскулап, СПб., 1999; 256

13. Кочубей ЛН, Виноградова ОМ, Серов ВВ, Васильева НА. Прогноз и выживаемость больных вторичным амилоидозом (анализ 146 случаев). Тер арх 1993; 6: 48-54

14. Tuglular S, Yalcinkaya F, Paydas S et al. A retrospective analysis for aetiology and clinical findings of 287 secondary amyloidosis cases in Turkey. Nephrol Dial Transplant 2002; 17: 2003-2005

15. Potysova Z, Merta M, Tesar V et al. Renal AA amyloidosis: survey of epidemiologic and laboratory data from one nephrology centre. Int Urol Nephrol 2009; 41: 941–945

16. De Beer FC, Mallya RK, Fagan EA et al. Serum amyloid A protein concentration in inflammatory diseases and its relationship to the incidence of reactive systemic amyloidosis. Lancet 1982; 2: 231–234

17. Husebekk A, Skogen B, Husby G, Marhaug G. Transformation of amyloid precursor SAA to protein AA and incorporation in amyloid fibrils in vivo. Scand J Immunol 1985; 21: 283-287

18. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997; 25: 898-909

19. Шишкин АН. Амилоидные болезни. Медицина XXI века 2008; 9(10): 44-51

20. Малкоч АВ, Хасабов НН. Амилоидоз. В: Таболин ВА, Бельмер СВ, Османов ИМ, ред. Нефрология детского возраста. ИД МЕДПРАКТИКА-М, М., 2005; 519-538

21. Hijmans W, Sipe JD. Levels of the serum amyloid A protein (SAA) in normal persons of different age groups. Clin Exp Immunol 1979; 35: 96-100

22. Wilkins J, Gallimore JR, Tennent GA et al. Rapid Automated Enzyme Immunoassay of Serum Amyloid A. Clin Chem 1994; 40(7): 1284-1290

23. Lannergård A, Friman G, Ewald U et al. Serum amyloid A (SAA) protein and high-sensitivity C-reactive protein (hsCRP) in healthy newborn infants and healthy young through elderly adults. Acta Paediatr 2005; 94(9): 1198-1202

24. Li TW, Zheng BR, Huang ZX et al. Screening diseaseassociated proteins from sera of patients with rheumatoid arthritis: a comparative proteomic study. Chin Med J 2010; 123(5): 537-543

25. Cunnane G, Grehan S, Geoghegan S et al. Serum amyloid A in the assessment of early inflammatory arthritis. J Rheumatol 2000; 27: 58–63

26. Migita K, Eguchi K, Tsukada T et al. Increased circulating serum amyloid A protein derivatives in rheumatoid arthritis patients with secondary amyloidosis. Lab Invest 1996; 75: 371–375

27. Roсken C, Shakespeare A. Pathology, diagnosis and pathogenesis of AA amyloidosis. Virchows Arch 2002; 440: 111- 122

28. Chevrel G, Jenvrin C, McGregor B, Miossec P. Renal type AA amyloidosis associated with rheumatoid arthritis: a cohort study showing improved survival on treatment with pulse cyclophosphamide. Rheumatology 2001; 40: 821–825

29. Okuda Y, Takasugi K, Oyama T et al. Amyloidosis in rheumatoid arthritis: clinical study of 124 histologically proven cases. Ryumachi 1994; 34: 939-946

30. Тареев ЕМ, Борисов ИА. Поражение почек при ревматоидном артрите. В: Тареев ЕМ, ред. Клиническая нефрология. Том 2. Медицина, М., 1983; 189-200

31. Blank N, Lorenz HM. Diagnostics and therapy of AA amyloidosis. Pathologe 2009; 30(3): 219-225

32. Kuroda T, Wada Y, Kobayashi D et al. Effective anti-TNFalpha therapy can induce rapid resolution and sustained decrease of gastroduodenal mucosal amyloid deposits in reactive amyloidosis associated with rheumatoid arthritis. J Rheumatol. 2009; 36(11): 2409-2415

33. Nakamura T. Clinical strategies for amyloid A amyloidosis secondary to rheumatoid arthritis. Mod Rheumatol 2008; 18(2): 109-118

34. Connolly M, Veale DJ, Fearon U. Acute serum amyloid A regulates cytoskeletal rearrangement, cell matrix interactions and promotes cell migration in rheumatoid arthritis. Ann Rheum Dis 2011; 70(7): 1296-1303

35. Koivuniemi R, Paimela L, Suomalainen R et al. Amyloidosis is frequently undetected in patients with rheumatoid arthritis. Amyloid 2008; 15(4): 262-268

36. Рамеев ВВ, Козловская ЛВ, Малинина ЕА и др. Определение циркулирующих белков-предшественников амилоида в диагностике и мониторировании течения системного амилоидоза. Клиническая нефрология 2009; 55-62